Online inquiry

IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10467MR)

This product GTTS-WQ10467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10467MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13891MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ5178MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ11388MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ9746MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ6349MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ7964MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ6020MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ9565MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW